Key result
Precision medicine approaches, including the assessment of sex, genetics, intestinal microbiota, and endocrine status, may help tailor diagnosis and management for patients with NAFLD/MAFLD.
Why the study?
Multiple genetic, clinical, and environmental factors determine NAFLD/MAFLD heterogeneity, prompting the need to explore precision medicine-oriented approaches for individualized management and targeted therapy development.
A precision medicine approach considering genetics, microbiota, and metabolic factors may help identify homogeneous NAFLD patient subgroups for better targeted therapies.
Answers are grounded in this paper and cite their sources.
Merits evaluation in NAFLD/MAFLD care; leaves open prospective trials before routine adoption.
Precision medicine defines the attempt to identify the most effective approaches for specific subsets of patients based on their genetic background, clinical features, and environmental factors. Nonalcoholic fatty liver disease (NAFLD) encompasses the alcohol-like spectrum of liver disorders (steatosis, steatohepatitis with/without fibrosis, and cirrhosis and hepatocellular carcinoma) in the nonalcoholic patient. Recently, disease renaming to MAFLD [metabolic (dysfunction)-associated fatty liver disease] and positive criteria for diagnosis have been proposed. This review article is specifically devoted to envisaging some clues that may be useful to implementing a precision medicine-oriented approach in research and clinical practice. To this end, we focus on how sex and reproductive status, genetics, intestinal microbiota diversity, endocrine and metabolic status, as well as physical activity may interact in determining NAFLD/MAFLD heterogeneity. All these factors should be considered in the individual patient with the aim of implementing an individualized therapeutic plan. The impact of considering NAFLD heterogeneity on the development of targeted therapies for NAFLD subgroups is also extensively discussed.
No takes yet. Share an insight, caveat, or question.
Lonardo et al. (2021) conducted a review in Nonalcoholic fatty liver disease (NAFLD) / Metabolic-associated fatty liver disease (MAFLD). Precision medicine approaches was evaluated. Precision medicine approaches, including the assessment of sex, genetics, intestinal microbiota, and endocrine status, may help tailor diagnosis and management for patients with NAFLD/MAFLD.
Synapse has enriched 10 related papers. Consider them for comparative context: